The invention introduces high-flux nanocomposite hollow fiber membranes, particularly designed for hemodialysis. Composed of polyether sulfone (PES), Vitamin E TPGS (Vit. E TPGS), and nanozeolite (NZ), these membranes offer enhanced performance in kidney dialysis by improving biocompatibility and filtration efficiency.
There is a critical need for more efficient and biocompatible hemodialysis membranes. Traditional membranes often fail to adequately filter blood impurities and can trigger negative reactions such as blood cell damage and inflammatory responses, necessitating the development of more effective alternatives.
- Biocompatibility: Incorporation of Vitamin E TPGS reduces hemolysis and platelet adhesion, enhancing biocompatibility.
- Enhanced Filtration Efficiency: The nanozeolite inclusion improves the structural porosity of the membranes, leading to better filtration performance.
- High Flux Capabilities: Designed to allow higher rates of blood processing, reducing dialysis time while maintaining effectiveness.
The prototype membranes demonstrated superior hemocompatibility and efficiency in pre-clinical tests. They showed significantly lower fouling, higher ultrafiltration coefficients, and improved solute rejection rates compared to conventional membranes.
The high-flux nanocomposite hollow fiber membranes for hemodialysis are at the advanced prototype stage, showing improved biocompatibility and efficiency in pre-clinical tests. The technology is preparing for clinical trials, aiming to enhance dialysis treatment for chronic kidney disease patients.
5
By improving the efficiency and safety of hemodialysis, these membranes can significantly enhance the quality of life for patients with chronic kidney diseases. They promise to make dialysis more accessible and less burdensome, potentially reducing the healthcare costs associated with kidney failure management.
Healthcare, Medical Devices, Materials
- Medical Devices: Specifically useful in the manufacturing of dialyzers for hemodialysis.
- Healthcare: Direct application in treatments for chronic kidney disease (CKD), especially in managing end-stage renal disease (ESRD).
Geography of IP
Type of IP
201721012546
421208